FigsharePub Date : 2024-02-21DOI: 10.1021/acsnano.3c10547.s001
Yaoying Long (18003796), Bianlei Yang (18003799), Qian Lei (450971), Fei Gao (29262), Li Chen (5749), Wenlan Chen (846226), Siyi Chen (6525728), Wenxiang Ren (18003802), Yulin Cao (2163637), Liuyue Xu (13540498), Di Wu (23906), Jiao Qu (849408), He Li (176971), Yali Yu (5117996), Anyuan Zhang (6030050), Shan Wang (120085), Weiqun Chen (121146), Hongxiang Wang (433625), Ting Chen (15205), Zhichao Chen (846227), Qiubai Li (306378)
{"title":"TargetingnSenescent Alveolar Epithelial Cells UsingnEngineered Mesenchymal Stem Cell-Derived Extracellular Vesicles TonTreat Pulmonary Fibrosis","authors":"Yaoying Long (18003796), Bianlei Yang (18003799), Qian Lei (450971), Fei Gao (29262), Li Chen (5749), Wenlan Chen (846226), Siyi Chen (6525728), Wenxiang Ren (18003802), Yulin Cao (2163637), Liuyue Xu (13540498), Di Wu (23906), Jiao Qu (849408), He Li (176971), Yali Yu (5117996), Anyuan Zhang (6030050), Shan Wang (120085), Weiqun Chen (121146), Hongxiang Wang (433625), Ting Chen (15205), Zhichao Chen (846227), Qiubai Li (306378)","doi":"10.1021/acsnano.3c10547.s001","DOIUrl":"https://doi.org/10.1021/acsnano.3c10547.s001","url":null,"abstract":"Type 2 alveolar epithelialncell (AEC2) senescence is crucial tonthe pathogenesis of pulmonary fibrosis (PF). The nicotinamide adeninendinucleotide (NAD<sup>+</sup>)-consuming enzyme cluster of differentiationn38 (CD38) is a marker of senescent cells and is highly expressed innAEC2s of patients with PF, thus rendering it a potential treatmentntarget. Umbilical cord mesenchymal stem cell (MSC)-derived extracellularnvesicles (MSC-EVs) have emerged as a cell-free treatment with clinicalnapplication prospects in antiaging and antifibrosis treatments. Herein,nwe constructed CD38 antigen receptor membrane-modified MSC-EVs (CD38-ARM-MSC-EVs)nby transfecting MSCs with a lentivirus loaded with a CD38 antigennreceptor–CD8 transmembrane fragment fusion plasmid to targetnAEC2s and alleviate PF. Compared with MSC-EVs, the CD38-ARM-MSC-EVsnengineered in this study showed a higher expression of the CD38 antigennreceptor and antifibrotic miRNAs and targeted senescent AEC2s cellsnhighly expressing CD38 in vitro and in naturally aged mouse modelsnafter intraperitoneal administration. CD38-ARM-MSC-EVs effectivelynrestored the NAD<sup>+</sup> levels, reversed the epithelial–mesenchymalntransition phenotype, and rejuvenated senescent A549 cells in vitro,nthereby mitigating multiple age-associated phenotypes and alleviatingnPF in aged mice. Thus, this study provides a technology to engineernMSC-EVs and support our CD38-ARM-MSC-EVs to be developed as promisingnagents with high clinical potential against PF.","PeriodicalId":522379,"journal":{"name":"Figshare","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147896098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}